替可克肽治疗产妇硬膜穿刺后头痛无效:双盲随机对照试验
这项双盲随机对照试验在两家三级产科医院纳入产后硬膜穿刺后头痛(PDPH)患者,比较替可克肽1 mg静脉注射与安慰剂。期中分析44例时,治疗组91%与安慰剂组86%需硬膜外血补片(P=0.6575),无显著差异;治疗组住院时间延长1天(P=0.0486),研究因无效提前终止。
要点
- 替可克肽1 mg静脉注射不能减少产后PDPH患者硬膜外血补片需求。
- 治疗组与安慰剂组头痛强度、持续时间及活动受限无差异。
- 治疗组住院时间较安慰剂组延长1天(P=0.0486)。
核心结论
- 单剂替可克肽对产后PDPH预防硬膜外血补片需求无效,对头痛强度、持续时间及活动受限无影响。
- 鉴于上述结果,促肾上腺皮质激素类似物不应考虑用于该适应证。
研究设计与样本
- 随机、双盲、安慰剂对照试验,在两家三级产科医院进行。
- 产后椎管内麻醉后发生PDPH的患者随机接受替可克肽1 mg静脉注射或安慰剂。
- 主要结局为15天随访内硬膜外血补片(EBP)实施率;计划在入组50%时进行无效性期中分析。
主要发现
- 期中分析纳入44例(治疗组23例,安慰剂组21例),主要结局无显著差异:治疗组21例(91%)与安慰剂组18例(86%)接受EBP(P=0.6575)。
- 次要结局组间相当,但治疗组住院时间延长1天(P=0.0486)。
- 研究因无效而终止;未观察到替可克肽给药的副作用。
关键数值与推荐
- 主要结局:15天随访内EBP实施率,治疗组91% vs 安慰剂组86%,P=0.6575。
- 住院时间:治疗组较安慰剂组延长1天,P=0.0486。
临床怎么用
- 不推荐促肾上腺皮质激素类似物用于产后PDPH的治疗。
- 产后PDPH仍需以硬膜外血补片等有效治疗为主。
局限性
- 研究因无效提前终止,最终样本量较小(期中分析44例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postdural puncture headache (PDPH) is a common complication of neuraxial anaesthesia in obstetrics. Although epidural blood patch (EBP) remains the most effective treatment, less invasive alternatives are being explored. We assessed the efficacy and safety of tetracosactide, a synthetic adrenocorticotropic hormone analogue, for treating established PDPH in postpartum patients. METHODS: A randomised, double-blind, placebo-controlled trial was conducted in two tertiary care maternal hospitals. Postpartum patients with PDPH after neuraxial anaesthesia were randomised to receive either tetracosactide 1 mg i.v. or placebo. The primary outcome was the rate of EBP within the 15-day follow-up. Secondary outcomes included headache duration and intensity, activity limitation, length of hospital stay, and the number of EBPs performed per patient. Interim analysis to determine futility and trial termination was planned at 50% enrolment. RESULTS: At interim analysis with 44 patients enrolled (23 in the treatment group and 21 in the placebo group) no significant difference was found for the primary outcome: 21 (91%) patients in the treatment group and 18 (86%) patients in the placebo group received EBP (P=0.6575). Secondary outcomes were comparable between groups, except for a 1-day longer hospital stay in the treatment group (P=0.0486). The study was terminated because of futility. No side-effects of tetracosactide administration were observed. CONCLUSIONS: A single dose of tetracosactide did not demonstrate efficacy in preventing EBP needs in postpartum PDPH, and there was no effect on the intensity, duration of headaches, and physical activity limitations. Given these findings, adrenocorticotropic hormone analogues should not be considered for this indication. CLINICAL TRIAL REGISTRATION: European Union Clinical Trials Register (2015-003357-17); ClinicalTrials.gov (NCT02813655); French Agence Nationale de Sécurité du Médicament et des Produits de Santé (160214A-31).
引用
- Dziadzko M, Bouvet L, Steer N, et al. No effect of tetracosactide for treatment of postdural puncture headaches in parturient women: a double-blind randomised controlled clinical trial. Br J Anaesth. 2025. PMID: 40393818. doi:10.1016/j.bja.2025.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。